- Home
- OGI vs SWKH Comparison
OGI vs SWKH Comparison
Compare OGI & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- SWKH
- Stock Information
- Founded
- OGI 2013
- SWKH 1996
- Country
- OGI Canada
- SWKH United States
- Employees
- OGI N/A
- SWKH N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- SWKH Diversified Financial Services
- Sector
- OGI Health Care
- SWKH Finance
- Exchange
- OGI Nasdaq
- SWKH Nasdaq
- Market Cap
- OGI 170.2M
- SWKH 202.7M
- IPO Year
- OGI N/A
- SWKH 1999
- Fundamental
- Price
- OGI $1.31
- SWKH $17.11
- Analyst Decision
- OGI
- SWKH
- Analyst Count
- OGI 0
- SWKH 0
- Target Price
- OGI N/A
- SWKH N/A
- AVG Volume (30 Days)
- OGI 1.3M
- SWKH 6.8K
- Earning Date
- OGI 02-11-2025
- SWKH 03-20-2025
- Dividend Yield
- OGI N/A
- SWKH N/A
- EPS Growth
- OGI N/A
- SWKH N/A
- EPS
- OGI N/A
- SWKH 0.84
- Revenue
- OGI $115,451,336.00
- SWKH $24,725,000.00
- Revenue This Year
- OGI $50.11
- SWKH N/A
- Revenue Next Year
- OGI $16.16
- SWKH $6.17
- P/E Ratio
- OGI N/A
- SWKH $20.40
- Revenue Growth
- OGI N/A
- SWKH N/A
- 52 Week Low
- OGI $1.24
- SWKH $15.14
- 52 Week High
- OGI $2.91
- SWKH $18.49
- Technical
- Relative Strength Index (RSI)
- OGI 38.71
- SWKH 61.49
- Support Level
- OGI $1.27
- SWKH $16.42
- Resistance Level
- OGI $1.38
- SWKH $17.25
- Average True Range (ATR)
- OGI 0.10
- SWKH 0.23
- MACD
- OGI -0.03
- SWKH 0.06
- Stochastic Oscillator
- OGI 14.00
- SWKH 88.71
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds brands, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.